Energy & Environmental Law Adviser
Product Liability & Mass Torts Blog
Employment Law Landscape
The Center for Biosimilars
Hatch-Waxman and Biosimilars Practice Group Leader Imron Aly was quoted on why patients in the United States may have to wait longer than those in the European Union for the biosimilar adalimumab, referencing the brand name drug, Humira.
“The Humira question is really an interesting one. In Europe the patent litigations had already been underway, whereas in the U.S., they were trailing a little bit behind,” Imron said. “So once the first filer for any biosimilar product settled in Europe — setting the dates and everything that went with that — it made it harder for others to challenge it in the U.S. and be incentivized to continue litigation when there was a sure bet and a sure launch date coming up that probably couldn’t have been beaten anyways with a long, drawn-out fight.”
Watch the clip here.
This publication has been prepared for the general information of clients and friends of the firm. It is not intended to provide legal advice with respect to any specific matter. Under rules applicable to the professional conduct of attorneys in various jurisdictions, it may be considered attorney advertising material. Prior results do not guarantee a similar outcome.